title: [Does total androgen suppression in advanced prostatic cancer induce a greater number of complete remissions? A phase II trial].
abstract: The present Phase II study's main objective was to evaluate the rate of complete responses (CR) obtained through total androgenic suppression (TAS) in patients with disseminated prostate carcinoma. Twenty consecutive patients were recruited of which 19 were evaluable for response and toxicity. Treatment consisted in an association of orchiectomy or the analogous LH-RH Buselerin with the antiandrogenic Flutamide. There was 1 CR (5%) and 17 partial responses (PR). Sixteen patients with symptomatic disease had subjective improvement, usually during the first month of treatment. After an average follow-up of 20 months (range 7-29), 1 patient remains CR and 7 have regressed following PR, 4 of which have died. Tolerance was good, and side effects secondary to hypoandrogenism were frequent, although mild, requiring treatment discontinuation in 1 case. It is concluded that TAS is an excellent palliative approach in disseminated prostate carcinoma though the rate of CRs obtained is sensibly lower to that reported by Labrie (28.3%) and in the range of 0-8% achieved in most studies. It is questionable whether it will become standard therapy for metastatic prostate carcinoma.
authors.affiliation: Unidad de Oncología Médica, Servicio de Oncología H.S.C.S.P, Barcelona.
authors.forename: J R
authors.initials: JR
authors.lastname: Germà Lluch
authors.forename: M A
authors.initials: MA
authors.lastname: Izquierdo Delso
authors.forename: M A
authors.initials: MA
authors.lastname: Seguí Palmer
authors.forename: H
authors.initials: H
authors.lastname: Villavicencio
authors.forename: B
authors.initials: B
authors.lastname: Ojeda González
authors.forename: L
authors.initials: L
authors.lastname: de Andrés Basauri
authors.forename: C
authors.initials: C
authors.lastname: Pallarés Curto
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction
chemical_list: D005485:Flutamide; D000135:Acid Phosphatase; D002064:Buserelin
vernacular_title: Induce la supresión androgénica total en cáncer de próstata avanzado mayor no. de remisiones completas? Un ensayo en fase II.